KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. (gut.bmj.com)

Authors: Liu J … Hao J Journal: Gut Published: 2026-05-12 DOI: https://doi.org/10.1136/gutjnl-2025-336277